TFPI inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Methods for Purifying Pertussis Toxin and Peptides Useful Therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT). 151-. (canceled)52. A reagent comprising a peptide and a nucleic acid sequence encoding the peptide , the peptide having the amino acid sequence CVKKDELCXXXXXXCCEPLECXXXXXXXXXC , where X is any amino acid.531. The reagent of claim wherein the nucleic acid sequence is ribonucleic acid (RNA).541. The reagent of claim wherein the nucleic acid sequence is deoxyribonucleic acid (DNA).55. A method for generating a DNA-peptide fusion , said method comprising:{'claim-ref': {'@idref': 'CLM-00053', 'claim 53'}, '(a) covalently bonding a nucleic acid reverse-transcription primer to a peptide acceptor of a reagent of ;'}(b) translating the RNA to produce the peptide covalently bound to the reverse- transcription primer; and,(c) reverse transcribing said RNA to produce a DNA-peptide fusion.56. A method for purifying pertussis toxin comprising contacting a biological solution containing pertussis toxin with a DNA-peptide fusion produced by the method of to produce a complex between the DNA-peptide fusion and pertussis toxin claim 55 , and isolating the pertussis toxin.57. The method of wherein pertussis toxin is released from the complex and isolated.58. The method of wherein the pertussis toxin is released from the complex by altering the pH of the environment surrounding the complex.59. The method of wherein the complex is exposed to a solution having an acidic pH.60. The method of wherein the complex is exposed to a solution having a basic pH.61. The method of wherein the pertussis toxin is released from the complex by altering the ionic strength of the environment surrounding the complex.62. The method of wherein the ionic strength is altered by exposing the complex to a solution having a high concentration of one or more ionic salts.63. The method of wherein the ionic salt is at least one of sodium chloride or magnesium chloride.64. The method of wherein the ionic salt is magnesium ...

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

PEPTIDE THERAPEUTICS THAT BIND VEGF AND METHODS OF USE THEREOF

The present invention provides peptides and mimetics thereof that bind to VEGF. In preferred embodiments, the peptides of the invention are D type optical isomers which can bind VEGF and which can inhibit or reduce VEGF biological activity.

Sorting and immobilization system for nucleic acids using synthetic binding systems

Methods are provided for producing an array of immobilized nucleic acids on an array device. The array device has a plurality of microlocations each having an electrode. At least one of the microlocations has a synthetic addressing unit coupled to the microlocation. The microlocation is the activated, usually by electronically biasing the electrode of the microlocation. The at least one microlocation is then contacted by a conjugate which has a nucleic acid and a synthetic binding unit. The conjugate is then coupled to the microlocation through an interaction between the synthetic binding unit and the synthetic addressing unit. In one embodiment, the synthetic binding unit and synthetic addressing unit may be pRNA, pDNA, or CNA.

TFPI inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Test system for detecting a splicing reaction and use therof

The invention relates to a homogenous test system containing the following: (a) at least one or more, identical or different mobile nucleic acids with at least one spliceable nucleic acid, containing at least one intron; (b) at least two probes, containing corresponding fluorophores which preferably bind with the 5′ and/or 3′ ends of an exon/intron; (c) at least one gel-free detecting system for detecting a splicing reaction; and optionally (d) at least one composition containing splicing components; and (e) other auxiliary agents.

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics. 1. A method of inhibiting kallikrein activity in an eye , said method comprising delivery of a peptide to an eye of a subject , said peptide comprising an amino acid sequence having at least 80% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-239.2. The method of claim 1 , wherein said peptide is delivered as part of a pharmaceutical composition.3. The method of claim 2 , wherein delivery of said pharmaceutical composition is selected from one or more of topical delivery and intravitreal delivery.4. The method of claim 3 , wherein said pharmaceutical composition comprises an implant and wherein said implant provides sustained release of said peptide.5. The method of claim 4 , wherein said implant comprises a biodegradable polymer.6. The method of comprising intravitreal delivery claim 2 , wherein said pharmaceutical composition is delivered by injection to a posterior section of the eye.7. The method of comprising sustained release of said peptide from said pharmaceutical composition.8. The method of claim 7 , wherein said pharmaceutical composition comprises a reservoir.9. The method of claim 7 , wherein said pharmaceutical composition comprises at least one of a microemulsion claim 7 , a microsphere claim 7 , a liposome claim 7 , and a nanoparticle.10. The method of claim 10 , wherein said pharmaceutical composition comprises a biodegradable polymer.11. The method of claim 6 , wherein kallikrein activity is inhibited in at least one of the retina and the macula.12. The method of claim 11 , wherein the subject has at least one disorder selected from one or more of retinopathy claim 11 , diabetic retinopathy claim 11 , macular degeneration claim 11 , wet age-related macular degeneration claim 11 , macular edema claim 11 , diabetic macular edema claim 11 , and retinal ...

Enzymatic modification of a nucleic acid-synthetic binding unit conjugate

The present invention relates to conjugates of synthetic binding units and nucleic acids. The present invention also relates to methods for sorting and immobilizing nucleic acids on support materials using such conjugates by specific molecular addressing of the nucleic acids mediated by the synthetic binding systems. Particularly, the present invention also relates to novel methods of utilizing conjugates of synthetic binding units and nucleic acids to in active electronic array systems to produce novel array constructs from the conjugates, and the use of such constructs in various nucleic acid assay formats. In addition, the present invention relates to various novel forms of such conjugates, improved methods of making solid phase synthesized conjugates, and improved methods of conjugating pre-synthesized synthetic binding units and nucleic acids. The present invention also relates to the use of conjugates of synthetic binding units and nucleic acids as substrates for various enzymatic ...

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

HAIR-BINDING PEPTIDES

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

PMMA BINDING PEPTIDES

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

TFPI INHIBITORS AND METHODS OF USE

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Peptide and peptidomimetic inhibitors

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

TFPI INHIBITORS AND METHODS OF USE

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. 132.-. (canceled)33. A peptide that binds TFPI , comprising the following structure of formula V:{'br': None, 'X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023\u2003\u2003(V) (SEQ ID NO: 3118)'}wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;wherein X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;wherein X2005 is W;wherein X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;wherein X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;wherein X2008 is an amino acid selected from the group consisting of A, G, R, S and T;wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;wherein X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, ...

PMMA BINDING PEPTIDES

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

PMMA binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

TFPI inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

PMMA BINDING PEPTIDES

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

PMMA BINDING PEPTIDES

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

HAIR-BINDING PEPTIDES

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

HAIR-BINDING PEPTIDES

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

PMMA BINDING PEPTIDES

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Peptide and peptidomimetic inhibitors

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Clay-binding peptides and methods of use

Combinatorially generated peptides are provided that have binding affinity for clay. The peptides may be used to deliver benefit agents to various clay surfaces.

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

Sorting and immobilization system for nucleic acids using synthetic binding systems

The present invention relates to conjugates of synthetic binding units and nucleic acids. The present invention also relates to methods for sorting and immobilizing nucleic acids on support materials using such conjugates by specific molecular addressing of the nucleic acids mediated by the synthetic binding systems. Particularly, the present invention also relates to novel methods of utilizing conjugates of synthetic binding units and nucleic acids to in active electronic array systems to produce novel array constructs from the conjugates, and the use of such constructs in various nucleic acid assay formats. In addition, the present invention relates to various novel forms of such conjugates, improved methods of making solid phase synthesized conjugates, and improved methods of conjugating pre-synthesized synthetic binding units and nucleic acids. The present invention also relates to the use of conjugates of synthetic binding units and nucleic acids as substrates for various enzymatic reactions, including nucleic acid amplification reactions.

Peptide and peptidomimetic inhibitors

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

TFPI INHIBITORS AND METHODS OF USE

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. 155.-. (canceled)56. A peptide that binds TFPI , comprising the following structure of formula (VIII):X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (SEQ ID NO: 3120):wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L;wherein X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;wherein X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;wherein X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;wherein X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;wherein X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;wherein X3011 is an amino acid selected from the group ...

Internal combustion engine with cooling system and exhaust gas recirculation system

In an internal combustion engine with a cooling system and an exhaust gas recirculation (EGR) system including an EGR heat exchanger with a coolant inlet opening connected to a coolant outlet opening of the engine for receiving coolant therefrom and the engine including a coolant collecting rail mounted directly to the engine and having a coolant inlet opening connected to the EGR heat exchanger and at least one other coolant inlet opening in communication directly with at least one other coolant outlet opening of the engine.

Methods for Purifying Pertussis Toxin and Peptides Useful Therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT). 151-. (canceled)53. The method of wherein the immobilized peptide comprises the amino acid sequence RSNVIPLNEVWYDTGWDRPHRSRLSIDDDA (SEQ ID NO.: 70).54. The method of wherein the pertussis toxin is isolated from a fermentation supernatant.55. The method of wherein the peptide is immobilized by binding to a solid support.56. The method of wherein the solid support is selected from selected from the group consisting of a column claim 55 , chromatographic media claim 55 , column material claim 55 , bead claim 55 , test tube claim 55 , microtiter dish claim 55 , solid particle claim 55 , sepharose claim 55 , agarose claim 55 , microchip claim 55 , silicon claim 55 , silicon-glass claim 55 , gold claim 55 , and a membrane.57. The method of wherein the pertussis toxin is eluted from the peptide using a buffer comprising glycine claim 52 , carbonate or magnesium.58. The method of wherein the buffer comprises glycine at about pH 2.5.59. The method of wherein the buffer comprises carbonate at about pH 10.5.60. The method of wherein the buffer comprises MgCl.61. The method of wherein the solid support is a sepharose bead comprising 300-400 pmol of the peptide.62. The method of comprising a complex of a peptide and a solid support.63. The method of wherein the pertussis toxin is immobilized to a complex of a peptide and a solid support claim 62 , the method further comprising eluting the pertussis toxin from the complex and regenerating the complex.64. The method of wherein the complex is regenerated using HCl.65. The method of wherein the immobilized peptide comprises the amino acid sequence RSNVIPLNEVWYDTGWDRPHRSRLSIDDDA (SEQ ID NO.: 70) and the pertussis toxin is eluted from the peptide using a buffer comprising glycine at about pH 2.5 or carbonate at about pH 10.5. This application is a continuation U.S. Ser. No. 13/561,471 filed Jul. 30, 2012, which is a continuation of U.S. Ser. No. ...

CLAY-BINDING PEPTIDES AND METHODS OF USE

Combinatorially generated peptides are provided that have binding affinity for clay. The peptides may be used to deliver benefit agents to various clay surfaces.

Internal combustion engine with cooling system and exhaust gas recirculation system

In an internal combustion engine with a cooling system and an exhaust gas recirculation (EGR) system including an EGR heat exchanger with a coolant inlet opening connected to a coolant outlet opening of the engine for receiving coolant therefrom and the engine including a coolant collecting rail mounted directly to the engine and having a coolant inlet opening connected to the EGR heat exchanger and at least one other coolant inlet opening in communication directly with at least one other coolant outlet opening of the engine.

Peptide and peptidomimetic inhibitors

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Hair-binding peptides

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF

The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use. 6. (canceled)7. A composition comprising the compound of and a pharmaceutically acceptable excipient.8. A kit comprising the compound of and at least one device selected from the group consisting of a labeling device claim 1 , a purification device claim 1 , a handling device claim 1 , a radioprotection device claim 1 , an analytical device claim 1 , and an administration device.9. The compound of claim 4 , wherein the compound comprises the diagnostically active nuclide.10. The compound of claim 9 , wherein the diagnostically active nuclide is selected from the group consisting of Sc claim 9 , Sc claim 9 , Mn claim 9 , Mn claim 9 , Cu claim 9 , Ga claim 9 , Ga claim 9 , Y claim 9 , Zr claim 9 , Tc claim 9 , Tc claim 9 , In claim 9 , Tb claim 9 , Tb claim 9 , Tl claim 9 , Pb claim 9 , F claim 9 , Br claim 9 , Br claim 9 , I claim 9 , I claim 9 , and I.11. The compound of claim 9 , wherein the diagnostically active nuclide is selected from the group consisting of Sc claim 9 , Sc claim 9 , Cu claim 9 , Ga claim 9 , Ga claim 9 , Y claim 9 , Zr claim 9 , Tc claim 9 , In claim 9 , Tb claim 9 , Tb claim 9 , Pb claim 9 , F claim 9 , Br claim 9 , Br claim 9 , I claim 9 , I claim 9 , and I.12. The compound of claim 9 , wherein the diagnostically active nuclide is selected from the group consisting of Cu claim 9 , Ga claim 9 , Zr claim 9 , Tc claim 9 , In claim 9 , F claim 9 , I claim 9 , and I.13. The compound of claim 4 , wherein the compound comprises the therapeutically active nuclide.14. The compound of claim 13 , wherein the therapeutically active radionuclide is selected from the group consisting of Sc claim 13 , Cu claim 13 , Sr claim 13 , Y claim 13 , Sm claim 13 , Tb claim 13 , Tb claim 13 , Lu claim 13 , Re claim 13 , Re claim 13 , Pb claim 13 , Bi claim 13 , Ra claim 13 , Ac claim 13 , Th claim 13 , Th claim 13 , I claim 13 , and At.15. The compound of claim 13 ...

PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics. 2. (canceled)3. The peptide or peptide mimetic of claim 1 , wherein the peptide or peptide mimetic is cyclized by a reaction of the residues Xaa1 and Xaa5 with a reagent.4. The cyclic peptide or peptide mimetic of claim 2 , wherein the reagent is selected from the group consisting of: 1 claim 2 ,2-bis(bromomethyl)benzene claim 2 , 1 claim 2 ,3-bis(bromomethyl)benzene claim 2 , 1 claim 2 ,4-bis(bromomethyl)benzene claim 2 , 2 claim 2 ,6-bis(bromomethyl)pyridine claim 2 , and (E)-1 claim 2 ,4-dibromobut-2-ene claim 2 , 1 claim 2 ,2-bis(bromomethyl)-4-alkylbenzene claim 2 , wherein the alkyl group contains between 1 and 22 carbon atoms.5. The peptide or peptide mimetic of claim 1 , wherein the peptide or peptide mimetic is cyclized by a reaction of the residues Xaa1 claim 1 , Xaa5 and either Xaa9 claim 1 , Xaa11 or Xaa12 with tris(bromomethyl)benzene.6. (canceled)7. A peptide or peptide mimetic comprising the amino acid sequence: RXaa0 Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Rwherein:{'sub': '1', 'a. Ris selected from the group consisting of H, acyl groups containing a linear or branched, saturated or unsaturated hydrocarbon chain from 1 to 20 carbon atoms, amides, carbamates, ureas, PEG, hydroxyalkyl starch, polypeptides or proteins;'}b. Xaa0 is absent, or an amino acid selected from the group consisting of Met, norvaline Ala, Gly, Ser, Val, tert-butylglycine, Leu, phenylglycine, Ile, Pro, Tip, 7-azatryptophan, Phe, 4-fluorophenylalanine, Thr, Tyr, Val, Lys, N-methyl-methionine, N-methyl-norvaline, N-methyl-alanine, sarcosine, N-methyl-tert-butylglycine, N-methyl-leucine, N-methyl-phenylglycine, N-methyl-isoleucine, N-methyl-tryptophan, N-methyl-7-azatryptophan, N-methyl-phenylalanine, N-methyl-4-fluorophenylalanine, N-methyl-threonine, N-methyl-tyrosine, N-methyl-valine, and N-methyl-lysine;c. ...

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Peptides having affinity for poly (benzyl methacrylate-co-methacrylic acid) potassium salt copolymers and methods of use

Peptides are provided that have binding affinity for poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymers (“BzMA-binding peptides”). The BzMA-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-base reagents may be used to couple benefit agents to a poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymer surface or may be used to couple a benefit agent comprising a poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymer surface to a target surface, such as a body surface.

Engine brake for a diesel engine

Wallpaper with polyvinylidene chloride coating - to facilitate dry-stripping off substrate

Non-return valve for injection moulding extruder screw - consists of single piece ring which can be fitted and dismantled over shaped screw end without using tools

A non-return valve for the screw of an injection moulding machine has recesses which engage with an end piece (5) fitted to the screw end and so that it rotates with it. The ring shaped valve body (9) always extends beyond the tapered section (6) of the end piece (5) and has groove shaped recesses which mate with flats (7) on the taper (6). The end piece (5) and taper (6) are so proportioned that the valve ring (9) can be fitted and dismantled by moving it over the end piece (5) and taper (6). USE/ADVANTAGE - Non-return valve for exit from injection moulding extruder screw. Single piece construction which can be easily fitted and dismantled and gives good sealing.

Wide angle hinge

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Aminofatty acid amides from the reaction of an epoxidized fatty acid ester width a polyfunctional amine, and use as a crosslinking agent

Aminohydroxy fatty acid amides obtained by condensation from epoxidized fatty acid alkyl esters and polyfunctional aliphatic oligoamines may be employed as crosslinking agents for polyfunctional epoxide compounds used as adhesives and/or coating compositions. The preferred crosslinking agent represents the reaction product of (1) epoxidized stearic acid methyl ester and (2) ethylene diamine or diethylene triamine, and has the following formula: ##STR1##

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Sorting and immobilization system for nucleic acids using synthetic binding systems

The present invention relates to conjugates of synthetic binding units and nucleic acids. The present invention also relates to methods for sorting and immobilizing nucleic acids on support materials using such conjugates by specific molecular addressing of the nucleic acids mediated by the synthetic binding systems. Particularly, the present invention also relates to novel methods of utilizing conjugates of synthetic binding units and nucleic acids to in active electronic array systems to produce novel array constructs from the conjugates, and the use of such constructs in various nucleic acid assay formats. In addition, the present invention relates to various novel forms of such conjugates, improved methods of making solid phase synthesized conjugates, and improved methods of conjugating presynthesized synthetic binding units and nucleic acids. The present invention also relates to the use of conjugates of synthetic binding units and nucleic acids as substrates for various enzymatic reactions, including nucleic acid amplification reactions.

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Sorting and immobilization system for nucleic acids using synthetic binding systems

The present invention relates to conjugates of synthetic binding units and nucleic acids. The present invention also relates to methods for sorting and immobilizing nucleic acids on support materials using such conjugates by specific molecular addressing of the nucleic acids mediated by the snythetic binding systems. Particularly, the present invention also relates to novel methods of utilizing conjugates of synthetic binding units and nucleic acids to in active electronic array systems to produce novel array constructs from the conjugates, and the use of such constructs in various nucleic acid assay formats. In addition, the present invention relates to various novel forms of such conjugates, improved methods of making solid phase synthesized conjugates, and improved methods of conjugating pre-synthesized synthetic binding units and nucleic acids. The present invention also relates to the use of conjugates of synthetic binding units and nucleic acids as substrates for various enzymatic reactions, including nucleic acid amplification reactions.

WIDE OPENING ANGLE HINGE, ESPECIALLY FOR FURNITURE

CETTE CHARNIERE COMPREND UNE PARTIE FIXE 2 ET UNE PARTIE MOBILE 3 RELIEES ENTRE ELLES PAR DES BIELLETTES 8, 9. LA BIELLETTE 9 EST ARTICULEE A LA PARTIE MOBILE 3 PAR UNE BIELLETTE INTERMEDIAIRE 15. UN MECANISME A RESSORT 20 MONTE SUR LA BIELLETTE 15 COOPERE AVEC UNE CAME SOLIDAIRE DE LA PARTIE 3 POUR VERROUILLER LE BATTANT 7 DE LA PORTE EN POSITION DE FERMETURE. LE MECANISME COMPREND UN LEVIER 22 ARTICULE SUR LA BIELLETTE 15 ET SOLLICITE PAR UN RESSORT 27. CE LEVIER COOPERE AVEC UNE CAME SOLIDAIRE DE LA PARTIE FIXE 3 DE FACON QUE LA MANOEUVRE DE LA PORTE N'AIT A FRANCHIR UN POINT DUR QU'A L'INSTANT DU FRANCHISSEMENT DU VERROUILLAGE. THIS HINGE CONSISTS OF A FIXED PART 2 AND A MOBILE PART 3 CONNECTED TO ONE Another BY RODS 8, 9. THE ROD 9 IS ARTICULATED TO THE MOBILE PART 3 BY AN INTERMEDIATE ROD 15. A SPRING MECHANISM 20 MOUNTED ON THE ROD 15 COOPERATED WITH A CAMS IN PART OF PART 3 TO LOCK THE LEAF 7 OF THE DOOR IN THE CLOSED POSITION. THE MECHANISM INCLUDES A LEVER 22 ARTICULATED ON THE LINKAGE 15 AND SOLICITED BY A SPRING 27. THIS LEVER COOPERATES WITH A CAM IN SOLIDARITY OF THE FIXED PART 3 SO THAT THE OPERATION OF THE DOOR DOES NOT HAVE TO CROSS A HARD POINT ON THE L '' INSTANT OF THE LOCKING.

COMPRESSION DEVICE FOR STOPPING THE CIRCULATION IN A PART OF THE BODY

LE DISPOSITIF COMPREND UNE BANDE 3 MUNIE D'UNE BOUCLE 5 PERMETTANT DE FORMER UN BRACELET, DE LE SERRER ET DE LE BLOQUER SERRE. LA BANDE 3 PRESENTE SUR SA FACE TOURNEE VERS LE MEMBRE 2 DEUX NERVURES ETROITES 6A DE LONGUEUR LIMITEE ET PRESENTANT UN BORD CONCAVE 7. SOUS CHAQUE NERVURE, LA PRESSION SPECIFIQUE EST LOCALEMENT ELEVEE POUR COMPRIMER LE VAISSEAU VOULU, TANDIS QUE, SUR LE RESTE DU POURTOUR DU MEMBRE, LA PRESSION EST INSUFFISANTE POUR ARRETER LA CIRCULATION.

Methods for purifying pertussis toxin and peptides useful therefor

Engine brake for Diesel engine

The brake comprises a control line (11) which leads to a needle closer (10), which acts with the nozzle needle (9). The needle is in constant flow contact with the high pressure pump. When the decompression valve (5) is activated, the closer presses the needle into sealing contact on its needle seat (8). The needle closer is peg-shaped, and is positioned coaxially to the needle, between it and the control valve. This is formed as a bar-shaped short stroke valve (16) with a valve rod (16a) which has a smaller diameter in the area of its valve seat.

Method for purifying pertussis toxin and peptide useful therefor

【課題】百日咳毒素（ＰＴ）を精製するための試薬および方法を提供する。 【解決手段】アミノ酸配列ＮＶＩＰＬＮＥＶＷＹＤＴＧＷＤＲＰＨＲＳＲＬＳＩＤＤを含むペプチド。 【選択図】なし

Method and device for fine machining of ring-shaped workpieces

Engine brake device

Universal joint coupling

Tool for use in machine tools

A tool, in particular a fine-turning boring bar, for use in machine-tools, includes a shank part (16) which can be coupled to a rotating tool spindle, a head part (10) which is secured to the shank part (16) so as to remain fixed during rotation and which can be adjusted transversely with respect to the shank part (16), and a cutting support (20) which can be radially adjusted for coarse positioning purposes. Cylindrical fitting pins (28, 30) provided with radial face grooves (36, 38) are formed facing each other on the shank part (16) and the head part (10). A cross-coupling element (12) arranged between the front ends of the fitting pins (28, 30) has radially mobile pairs of claws (40, 42) which extend axially from both sides and which engage in mutually perpendicular face grooves (36, 38) in the fitting pins (28, 30). The two fitting pins (28, 30) also engage in mutually eccentric fitting holes (32, 34) of an eccentric sleeve (18) which can rotate with respect to the head part (10) and the shank part (16). The head part (10) and the shank part (16) are clamped temporarily, with radial play, by the cross-coupling element (12) and the eccentric sleeve (18) and then interconnected by means of a clamping anchor (14) which passes through the bore holes in the shank part (16), rotates in a thread (58) in the head part (10) and rests against an abutment (62, 64, 66) in the region of the shank part.

Pmma binding peptides

Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. 2fl/0Q/1 F

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Holding device for hose and other lines in medical facilities and in the field of nursing and elderly care

Tfpi inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Photographic-printing machine.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.

Surface grinding machine with workpieces in rotating holder - which is pulled against grinding band by magnet on other side of band

The grinding machine is for grinding the end faces of metal sealing rings and has the workpiece presses against a grinding band, pressing the rear of the band against a flat surface (=table), (5) which (5) consists partly or wholly of at least one magnet (7) located in a recess in the table. The magnet may be permanent or a controlled electromagnet. The workpiece (14) is held in a holder (8) located a given distance above the grinding band (2). The holder has several recesses to accommodate several workpieces and can rotate. The holder is rotated via a friction drive (10, 13) and can move linearly along guide rails in the direction of the movement of the band.

Optical projecting apparatus.

Peptide and peptidomimetic inhibitors

Kinetoscope.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X).

Engine brake for a diesel engine

DEVICE FOR ATTACHING A SECURITY LABEL

Hinge for flush-closing door wings

The hinge, as a concealed furniture hinge, has a hinge pin (4) which projects relative to the furniture parts (5, 6). The hinge part (2) fastened to the fixed furniture frame engages with at least one flat leg (22) into a groove (23) of the hinge part (3) fastened to the wing. On at least one side of the flat leg (22), there is provided, in the region of the hinge pin (4), an intermediate disc (24, 25) which is made of slidable material and which is arranged fixedly in terms of rotation. The intermediate discs (24, 25) can be connected to one another. <IMAGE>

TFPI inhibitors and methods of use

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Method for braking a four-stroke internal combustion engine, in particular for driving a vehicle

Compounds comprising a fibroblast activation protein ligand and use thereof

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

Compounds comprising a fibroblast activation protein ligand and use thereof

compostos que compreendem umligante de proteína de ativação de fibroblasto e uso dos mesmos. a presente invenção refere-se a um composto que compreende um peptídeo cíclico e um quelante, e seu uso. compounds comprising a fibroblast activating protein ligand and use thereof. the present invention relates to a compound comprising a cyclic peptide and a chelator, and its use.

Methods for purifying pertussis toxin and peptides useful therefor

The present invention relates to reagents and methods for purifying pertussis toxin (PT).

Prostate specific membrane antigen (psma) ligands and use thereof

The present disclosure is related to a compound of Formula (I)

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X).

Haltevorrichtung für schlauch- und andere leitungen an medizinischen einrichtungen sowie im bereich der kranken- und altenpflege

PEPTIDAKZEPTOR/tRNA-HYBRIDMOLEKÜL UND SEINE VERWENDUNG ZUR HERSTELLUNG VON CODON-SPEZIFISCH ARRETIERTEN TRANSLATIONSKOMPLEXEN

Die vorliegende Erfindung betrifft ein Peptidakzeptor/tRNA-Hybridmolekül, seine Verwendung als Substrat für die in vitro Translation einer mRNA zur Bildung von Codon-spezifisch, insbesondere Stopp-Codon-spezfisch arretierten Translationskomplexen. Auf diese Weise kann eine Genotyp/Phänotyp-Kopplung erreicht und/oder eine carboxyterminale Markierung in Proteine eingeführt werden. Die Codon-spezifisch-arretierten Translationskomplexe lassen sich beispielsweise für die selektive spezifische Degradation des 3'-untranslatierten Bereichs der kodierenden mRNA verwenden. Die vorliegende Erfindung eignet sich insbesondere für die Transkriptomanalyse und für in vitro Evolutionsanwendungen.

Ligandos de anhidrasa carbónica ix

Reivindicación 1: Un compuesto que comprende un péptido seleccionado entre el grupo que consiste en un péptido cíclico de fórmula (1a) en donde, en la fórmula (1a), la secuencia peptídica se dibuja de izquierda a derecha en dirección N-terminal a C-terminal, y Y (i) un grupo de modificación de extremo N-terminal A seleccionado entre el grupo que consiste en R⁰ᵃ-SO₂-, R⁰ᵃ-CO-, R⁰ᵃ-NH-CO-, en el que R⁰ᵃ se selecciona del grupo que consiste en alquilo (C₁-C₁₀), arilo (C₅-C₁₀) y alquilo (C₁-C₅)-arilo (C₅-C₁₀); o (ii) comprende un efector E1, tal como un quelante, en donde el efector E1 está unido de forma covalente a Xaa1 si Xaa1 está presente, o a Xaa2 si Xaa1 está ausente y Xaa2 está presente, o a Xaa3 si tanto Xaa1 como Xaa2 están ausentes, o (iii) es Z1, en donde Z1 comprende un resto enlazador L1 y un efector E1, tal como un quelante, en el que el resto enlazador L1 une de forma covalente el efector E1 a Xaa1 si Xaa1 está presente, o a Xaa2 si Xaa1 está ausente y Xaa2 está presente, o a Xaa3 si tanto Xaa1 como Xaa2 están ausentes; Xaa1 está presente o ausente, y si está presente es un residuo de un L-aminoácido alifático o polar; Xaa2 está presente o ausente, en donde si Xaa2 está ausente, Xaa1 también está ausente y, si Xaa2 está presente, (i) Xaa2 es un residuo de un L-a-aminoácido que está opcionalmente N-metilado en el átomo de nitrógeno, o, (ii) Xaa2 es un residuo de un L-a-aminoácido que comprende, además, de un grupo amino y un grupo carboxi unido a un átomo de a-C, un grupo funcional FG1 que forma un enlace covalente B1 con un grupo funcional FG2 de Xaa11, en donde Xaa11 es un resto de un L-a-aminoácido que comprende, además de un grupo amino y un grupo carboxi unido a un átomo de a-C, el grupo funcional FG2, en donde se forma un péptido bicíclico de fórmula (1b); Xaa3 es un residuo de un a-aminoácido de fórmula (2) en donde R³ᵃ y R³ᵇ se seleccionan cada uno e independientemente del grupo que consiste en H y CH₃; y Xaa3 es preferiblemente un residuo de un L ...

Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X)

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.

Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) (ver Fórmula) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X) (ver Fórmula).

Carbonic anhydrase ix ligands

The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.

Actuation device for an engine brake valve of an internal combustion engine

Panoramic tilting device.

Design for a puzzle box or case

Panoramic tilting device.

Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7 Yc (I) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X)

Consecutive-view apparatus.

Carbonic anhydrase ix ligands

The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.

Gastric inhibitory peptide receptor ligands

Carbonic anhydrase ix ligands

The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.

Projecting apparatus.

Adjustable duplex view-finder.

[UNK]

Combined dissolving-view apparatus and moving-picture machine.

Gastric inhibitory peptide receptor ligands

The present invention is related to compound comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib) each optionally comprising an N-terminal modification group A attached to Xaa1,and each optionally comprising a C-terminal group C-term attached to Xaa11.

Gastric inhibitory peptide receptor ligands

The present invention is related to compound comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib) each optionally comprising an N-terminal modification group A attached to Xaa1,and each optionally comprising a C-terminal group C-term attached to Xaa11.

Sortierungs und immobilisationssystem für nukleinsäuren mittels synthetischer bindungssysteme

Verfahren zum Beschleunigen eines Projektils in einer Druckluftschusswaffe und Druckluftschusswaffe zur Durchführung des Verfahrens

Compounds comprising a fibroblast activation protein ligand and use thereof

Compounds comprising a fibroblast activation protein ligand and use thereof

Werkzeug mit mindestens einem radial verstellbaren werkzeughalter.

Gastric inhibitory peptide receptor ligands

The present invention is related to compound comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib) each optionally comprising an N-terminal modification group A attached to Xaa1,and each optionally comprising a C-terminal group C-term attached to Xaa11.

Registering device for a moving-picture machine.

Ligandos de receptor de peptido inhibidor gastrico.

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (Ia) (Ver Fórmula) (Ia) o un péptido cíclico de la fórmula (Ib) (ver Fórmula) (Ib) cada uno opcionalmente comprendiendo un grupo de modificación en el extremo N, A, unido a Xaa1, y cada uno opcionalmente comprendiendo un C-término del grupo terminal C unido a Xaa11.

Schraubengetriebe für den Zahntiefenvorschub von Verzahnmaschinen mit einer Ballig- oder Konischverzahneinrichtung, insbesondere Stirnradwälzfräsmaschinen

Einrichtung zur probenentnahme fuer schuettgut

Die Erfindung betrifft eine Einrichtung zur Probenentnahme fuer Schuettgut aus einem Materialstrom. Waehrend das Ziel darin besteht, die Kosten zu senken und die Betriebssicherheit zu erhoehen, ist es die Aufgabe eine Einrichtung zu entwickeln, die ohne direkten Kontakt mit dem Foerdermaterial die Probe entnimmt. Die Loesung besteht darin, dass quer zur Foerderrichtung Druckgasstosserzeuger die Probenmaterialien in einen Auffangtrichter blasen, an welchem Probenbehaelter die Probe aufnehmen.

Gastric inhibitory peptide receptor ligands with bio-distribution modifier

The present invention is related to a compound comprising a cyclic peptide of formula (la) or a cyclic peptide of formula (lb), each comprising an N-terminal modification group A comprising a bio-distribution modifier, wherein the N-terminal modification group A is attached to Xaa1, and each comprising a C-terminal group C-term comprising a bio-distribution modifier, wherein the C-terminal group C-term is attached to Xaa11.

Carbonic anhydrase ix ligands

The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.